The analyses of PK, which are generally considered to be more sensitive than clinical efficacy end points 24 , showed a clear trend toward lower C trough levels in antidrug antibody–positive patients than in antidrug antibody–negative patients in both the SB5 and reference ADA groups.
← all excerpts
Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.
1
—
—